Name
Purdue University Globle
NU577 NP II Clinical – Women’s Health Focus
Prof. Name
Date
Sexually transmitted infections (STIs) such as trichomoniasis, syphilis, and chlamydia require early diagnosis, evidence-based treatment, partner management, and patient education to prevent transmission and long-term complications. According to the Centers for Disease Control and Prevention (CDC) STI Treatment Guidelines, recommended first-line therapies include metronidazole for trichomoniasis, benzathine penicillin G for uncomplicated syphilis, and doxycycline for uncomplicated chlamydia. Timely treatment, abstaining from sexual activity until therapy is complete, and ensuring that sexual partners receive evaluation and treatment are essential steps in reducing reinfection and improving patient outcomes.
Sexually transmitted infections remain a significant public health concern worldwide. Many infections are either asymptomatic or present with mild symptoms, allowing transmission to continue if they are not diagnosed and treated promptly. Untreated STIs can lead to serious complications, including pelvic inflammatory disease (PID), infertility, adverse pregnancy outcomes, neurological disease, and increased susceptibility to HIV infection.
Effective STI management includes:
Accurate diagnosis using recommended laboratory tests
Appropriate antimicrobial therapy
Partner notification and treatment
Patient education on prevention
Follow-up testing when indicated
Trichomoniasis is a common sexually transmitted infection caused by the protozoan parasite Trichomonas vaginalis. It primarily affects the urogenital tract and is more frequently diagnosed in women. Although many individuals remain asymptomatic, untreated infection increases the risk of acquiring and transmitting other STIs, including HIV.
Patients commonly present with:
Vaginal itching and irritation
Vaginal discomfort
Increased vaginal discharge
Dysuria (painful urination)
Thick white or frothy vaginal discharge
Strawberry cervix (punctate cervical hemorrhages) on pelvic examination
Diagnosis is confirmed through laboratory testing. Recommended methods include:
Wet mount microscopy (wet prep) to identify motile trichomonads
Nucleic acid amplification testing (NAAT), which offers the highest sensitivity and specificity
The CDC recommends:
Metronidazole 500 mg orally twice daily for 7 days
Patients should complete the entire antibiotic course even if symptoms resolve before treatment is finished.
Patient counseling should emphasize:
Avoid sexual intercourse until treatment is completed and symptoms have resolved.
Ensure all recent sexual partners receive treatment.
Take medications exactly as prescribed.
Use condoms consistently to reduce future STI risk.
Return for repeat testing approximately 3 months after treatment, as reinfection is common.
Referral is generally unnecessary unless complications, recurrent infections, or diagnostic uncertainty develops.
Syphilis is a bacterial sexually transmitted infection caused by Treponema pallidum. The disease progresses through several stages if left untreated and may eventually affect the cardiovascular and nervous systems.
Depending on the stage of infection, patients may present with:
Painless oral or genital ulcers (chancre)
Mucocutaneous lesions
Fever
Fatigue
Generalized lymphadenopathy
Elevated body temperature
Without treatment, syphilis may progress to latent or tertiary disease with neurological, cardiovascular, or systemic complications.
Diagnosis involves both screening and confirmatory testing:
Nontreponemal tests (RPR or VDRL)
Treponemal-specific tests (FTA-ABS, TP-PA, or EIA)
Patients with neurological symptoms should undergo further evaluation for possible neurosyphilis.
For uncomplicated primary, secondary, or early latent syphilis, the CDC recommends:
Benzathine penicillin G (Bicillin L-A) 2.4 million units intramuscularly in a single dose
Treatment recommendations differ for late latent syphilis, tertiary syphilis, or neurosyphilis.
Patients should understand the following:
Seek immediate medical care if neurological symptoms or mental status changes occur.
Sexual partners should be evaluated and treated when appropriate.
Abstain from sexual activity until treatment is completed and healthcare providers confirm it is safe to resume.
Consistent condom use lowers the risk of future STI transmission.
Patients should also be informed about the Jarisch-Herxheimer reaction, a temporary inflammatory response that may occur within the first 24 hours after treatment and can include:
Fever
Headache
Muscle aches
Chills
This reaction typically resolves without additional treatment.
Clinical and serologic follow-up is recommended according to CDC guidelines to confirm an adequate treatment response.
Syphilis is a reportable disease. Healthcare providers should notify local or state public health departments to facilitate disease surveillance and partner notification.
Chlamydia is one of the most frequently reported bacterial sexually transmitted infections and is caused by Chlamydia trachomatis. Because many infected individuals have no symptoms, routine screening plays an important role in early detection and prevention of complications.
Patients may experience:
Vaginal discharge
Thick white discharge
Dysuria
Pelvic discomfort
However, many patients remain asymptomatic until complications develop.
Untreated chlamydia may result in:
Pelvic inflammatory disease
Chronic pelvic pain
Ectopic pregnancy
Infertility
The preferred diagnostic method is:
Nucleic acid amplification testing (NAAT)
Acceptable specimens include:
Vaginal swabs
Cervical swabs
First-catch urine samples
The CDC recommends:
Doxycycline 100 mg orally twice daily for 7 days
Patients should complete the full course of antibiotics even if symptoms improve early.
Patients should be advised to:
Avoid sexual activity until treatment is completed.
Ensure all recent sexual partners are tested and treated.
Return promptly if symptoms such as pelvic pain, fever, persistent discharge, dyspareunia, or dysuria develop.
Practice consistent condom use to reduce future STI risk.
Routine test of cure is not recommended for most nonpregnant adults after appropriate treatment but repeat testing approximately 3 months after treatment is recommended because reinfection is common.
Referral is generally unnecessary unless patients develop complications such as pelvic inflammatory disease, recurrent infection, infertility concerns, or other reproductive health issues.
Successful STI management extends beyond prescribing antibiotics. Preventing reinfection requires comprehensive patient education and partner management.
Healthcare providers should encourage patients to:
Complete all prescribed medications.
Abstain from sexual activity until treatment is complete.
Inform recent sexual partners so they can receive testing and treatment.
Use condoms consistently and correctly.
Undergo routine STI screening based on age and individual risk factors.
Seek medical evaluation promptly if symptoms recur.
| STI | First-Line Treatment | Preferred Diagnostic Test | Important Follow-Up |
|---|---|---|---|
| Trichomoniasis | Metronidazole 500 mg orally twice daily for 7 days | NAAT or wet mount microscopy | Repeat testing approximately 3 months after treatment |
| Syphilis | Benzathine penicillin G 2.4 million units IM once (early syphilis) | Treponemal and nontreponemal serology | Clinical and serologic follow-up per CDC recommendations |
| Chlamydia | Doxycycline 100 mg orally twice daily for 7 days | NAAT | Repeat testing approximately 3 months after treatment |
The CDC recommends metronidazole 500 mg orally twice daily for 7 days as the preferred treatment for trichomoniasis in women.
The preferred treatment is doxycycline 100 mg orally twice daily for 7 days for most adolescents and adults with uncomplicated chlamydial infection.
Early syphilis is treated with benzathine penicillin G (Bicillin L-A) 2.4 million units administered intramuscularly as a single dose.
Yes. Recent sexual partners should be evaluated and treated when indicated to prevent reinfection and interrupt disease transmission.
Patients should abstain from sexual activity until they and their sexual partners have completed treatment and any symptoms have resolved, following current CDC recommendations.
Yes. Repeat testing approximately 3 months after treatment is recommended for patients treated for trichomoniasis and chlamydia because reinfection is common. Follow-up for syphilis is based on clinical evaluation and serial serologic testing.
Trichomoniasis, syphilis, and chlamydia require prompt diagnosis, CDC-recommended antimicrobial therapy, partner treatment, and patient education to reduce transmission and prevent complications. First-line treatments include metronidazole for trichomoniasis, benzathine penicillin G for early syphilis, and doxycycline for uncomplicated chlamydia. Appropriate follow-up testing and consistent condom use help reduce reinfection rates and improve long-term sexual health outcomes.
Centers for Disease Control and Prevention. (2021). Sexually transmitted infections treatment guidelines, 2021: Chlamydial infections. https://www.cdc.gov/std/treatment-guidelines/chlamydia.htm
Centers for Disease Control and Prevention. (2021). Sexually transmitted infections treatment guidelines, 2021: Syphilis. https://www.cdc.gov/std/treatment-guidelines/syphilis.htm
Centers for Disease Control and Prevention. (2021). Sexually transmitted infections treatment guidelines, 2021: Trichomoniasis. https://www.cdc.gov/std/treatment-guidelines/trichomoniasis.htm
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021). Sexually transmitted infections treatment guidelines, 2021. MMWR Recommendations and Reports, 70(4), 1–187. https://doi.org/10.15585/mmwr.rr7004a1
